McKesson Corporation vs Waste Management, Inc. — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Waste Management, Inc. trades at $208.83 (market cap $83.98B). The key difference: McKesson Corporation is the larger of the two by market cap, and Waste Management, Inc. pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Waste Management, Inc. for 130 Days on average.
| MCK | WM | |
|---|---|---|
Market Cap | $108.46B | $83.98B |
Volume | 712,607 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $995.69 | $246.51 |
52-Week Low | $725.17 | $196.77 |
Typical Hold Time | 74 Days | 130 Days |
Enterprise Value | $115.00B | $106.78B |
Dividend Yield | 0.4% | 1.8% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
WM trades at $210.10, up 0.56% today, with a bullish technical signal despite mixed moving average indicators. The company reported revenue of $25.20 billion in 2025 and maintains strong profitability with an 11.12% net income margin. Recent earnings show two beats and one miss, with Q3 2026 results expected soon. Analyst sentiment is positive with 54% buy ratings and no sell recommendations.
Outlook remains favorable due to consistent cash flow growth and strategic acquisitions, though elevated debt levels and competitive pressures pose risks. The stock offers a reliable dividend, with the next payment scheduled for September 2026. Investors should monitor Q3 earnings for confirmation of growth trajectory amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →